Reviva Pharmaceuticals Holdings Inc. (RVPH) - Total Liabilities
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has total liabilities worth $7.28 Trillion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Reviva Pharmaceuticals Holdings Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s total liabilities have evolved over time, based on quarterly financial data. See how liquid is Reviva Pharmaceuticals Holdings Inc.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Reviva Pharmaceuticals Holdings Inc. Competitors by Total Liabilities
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DEFSEC Technologies Inc.
NASDAQ:DFSC
|
USA | $4.09 Million |
|
Superior Resources Ltd
AU:SPQ
|
Australia | AU$546.28K |
|
TruCap Finance Limited
NSE:TRU
|
India | Rs3.42 Billion |
|
Anmol India Limited
NSE:ANMOL
|
India | Rs3.12 Billion |
|
Hube Yangfan Holding Co Ltd
SHG:600421
|
China | CN¥191.69 Million |
|
Mitra Energi Persada Tbk PT
JK:KOPI
|
Indonesia | Rp211.55 Billion |
|
COMTEC SOLAR SYS HD -004
F:8C11
|
Germany | €306.68 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Reviva Pharmaceuticals Holdings Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Reviva Pharmaceuticals Holdings Inc. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Reviva Pharmaceuticals Holdings Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Reviva Pharmaceuticals Holdings Inc. (2018–2025)
The table below shows the annual total liabilities of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.28 Trillion | +49525410.20% |
| 2024-12-31 | $14.69 Million | -18.30% |
| 2023-12-31 | $17.98 Million | +70.78% |
| 2022-12-31 | $10.53 Million | +287.46% |
| 2021-12-31 | $2.72 Million | -17.56% |
| 2020-12-31 | $3.30 Million | -51.62% |
| 2019-12-31 | $6.81 Million | +11.96% |
| 2018-12-31 | $6.09 Million | -- |
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, s… Read more